Optimum duration of neoadjuvant letrozole to permit breast conserving surgery

Breast Cancer Research and Treatment

Volumn 144, Issue 3, 2014, Pages 569-576

  Carpenter, Robert ^a   Doughty, Julie C ^b   Cordiner, Carolyn ^c   Moss, Nuala ^c   Gandhi, Ashu ^d   Wilson, Chris ^b   Andrews, Chris ^e   Ellis, Gillian ^f   Gui, Gerald ^g   Skene, Anthony I ^h  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c West of Scotland Breast Screening Service   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Novartis Pharmaceuticals UK Ltd   (United Kingdom)

^f CR Projects Ltd   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Breast conservation surgery; Letrozole; Neoadjuvant

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; OPEN STUDY; OSTEOPOROSIS; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; TUMOR INVASION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NITRILES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84899478355     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2835-8     Document Type: Article

References (16)

1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102
2. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027 (Pubitemid 46622110)
3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785 (Pubitemid 351264391)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
5. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244-254 (Pubitemid 47121883)
6. Bhatnagar AS (2007) The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 105(Suppl 1):7-17
7. Femara Prescribing Information: http://www.femara.com. Accessed 7 Sept 2011
8. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527-1532 (Pubitemid 34065880)
9. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G et al (2008) Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8:62
10. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM, et al (2004) Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 88(Suppl 1):S36-S37
11. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D et al (2009) Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113:145-151
12. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927-1934 (Pubitemid 350286227)
13. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF et al (2009) Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 208:906-914
14. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29:2342-2349
15. Moyer A (1997) Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol 16:284-298
16. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM et al (2009) Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 117:91-98